Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Virtus

Virtus KAR Health Sciences Fund A (RAGHX)

Ticker RAGHX · · Holdings as of Jun 30, 2026

Expense ratio
1.41%$141/yr per $10k
5-yr return
+2.4%annualized
1-yr return
+1.3%as of Dec 2025
Net assets
$91.7Mall share classes
Holdings
24

Bottom line

Is RAGHX a good fund? The bottom line

RAGHX is a share class of Virtus KAR Health Sciences Fund, an actively managed health care sector mutual fund from Virtus.

Annual fees run 1.41% — about $141 a year on every $10,000 invested, more expensive than 78% of health care sector funds we track.

It returned +1.3% over one year, +2.4% a year over five years, +6.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $91.7 million in net assets and 24 holdings, its largest position is Eli Lilly & Company (14.8%) and the top 10 make up 57.6% of the portfolio.

This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.41%)
  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 57.6% of assets
  • Front-end sales load up to 5.5%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What RAGHX invests in

The fund seeks long-term capital appreciation .

The fund pursues long-term capital appreciation in health sciences-related companies. The fund invests in a select group of health science-related companies believed by the funds subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. Under normal circumstances, the fund invests at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. As of the date of this prospectus, the fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. Although the fund may invest in companies of any market capitalization, the fund does not currently intend to invest more than 15% of its assets in…

From the fund's prospectus (filed Oct 22, 2026).

RAGHX performance

Average annual total returns
1 yr5 yr10 yr
RAGHX+1.3%+2.4%+6.2%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full RAGHX performance history →

What RAGHX costs

On a $10,000 investment, RAGHX's 1.41% expense ratio costs about $141 a year. The prospectus estimates $2,148 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full RAGHX fee table →

RAGHX top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY14.84%
2West Pharmaceutical Services Inc WST5.92%
3Abbvie Inc ABBV5.52%
4Vertex Pharmaceuticals Inc VRTX5.32%
5Merck & Company Inc MRK5.06%
6Unitedhealth Group Inc UNH4.65%
7Mckesson Corp MCK4.57%
8Mettler-toledo International Inc MTD3.99%
9Intuitive Surgical Inc ISRG3.89%
10Amgen Inc AMGN3.85%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 57.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to RAGHX

More funds like RAGHX →

RAGHX FAQ

What is the expense ratio of RAGHX?
RAGHX's expense ratio is 1.41%, which works out to about $141 a year for every $10,000 invested. The prospectus estimates total costs of $2,148 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RAGHX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.41%); 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 57.6% of assets; front-end sales load up to 5.5%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does RAGHX hold?
RAGHX's largest holdings are Eli Lilly & Company (14.8%), West Pharmaceutical Services Inc (5.9%), Abbvie Inc (5.5%), Vertex Pharmaceuticals Inc (5.3%), Merck & Company Inc (5.1%). It holds 24 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RAGHX's 5-year return?
RAGHX returned +2.4% a year over the five years ending Dec 31, 2025, and +6.2% a year over ten years. Past performance does not guarantee future results.
Does RAGHX have a sales load?
Yes. RAGHX has a maximum front-end sales charge of 5.5%.
Who manages RAGHX?
RAGHX is offered by Virtus through Virtus Investment Trust.